{"entity":{"type":"insider","cik":"0001668028","url":"/insider/0001668028","json_url":"/insider/0001668028.json","name":"Ally Bridge LB Management Ltd","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":17,"n_filings":6,"first":"2017-04-17","last":"2018-09-14","span_basis":"filed_date"},"name_variants":[{"name":"Ally Bridge LB Management Ltd","source":"filing","n_filings":6,"first_seen":"2017-04-17","last_seen":"2018-09-14"}],"transactions":[{"id":6142260,"accession":"0001209191-18-051069","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-051069","line_url":"/filing/0001209191-18-051069","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Yu Fan; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Ally Bridge LB Healthcare Master Fund Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Li Bin; ABG SRNE Ltd; ABG Management Ltd; ABG II-SO Ltd; Ally Bridge LB Management Ltd","owner_display_name":"Yu Fan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":107814.0,"shares_display":"107,814","price_per_share":4.94022272246647,"price_display":"4.94","price_state":"stated","total_value":532625.1726,"total_display":"532,625.17","total_whole":"532,625","shares_owned_after":1013020.0,"shares_owned_after_display":"1,013,020","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-13","filed_date":"2018-09-14","scope":"insider","n_lines":2},{"id":6142257,"accession":"0001209191-18-051069","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-051069","line_url":"/filing/0001209191-18-051069#line-1","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Yu Fan; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Ally Bridge LB Healthcare Master Fund Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Li Bin; ABG SRNE Ltd; ABG Management Ltd; ABG II-SO Ltd; Ally Bridge LB Management Ltd","owner_display_name":"Yu Fan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":189754.0,"shares_display":"189,754","price_per_share":5.0597,"price_display":"5.06","price_state":"stated","total_value":960098.3138,"total_display":"960,098.31","total_whole":"960,098","shares_owned_after":1120834.0,"shares_owned_after_display":"1,120,834","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-12","filed_date":"2018-09-14","scope":"insider"},{"id":6144161,"accession":"0001209191-18-008299","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-18-008299","line_url":"/filing/0001209191-18-008299#line-2","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG Management Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Li Bin; Ally Bridge LB Management Ltd; ABG II-SO Ltd; Yu Fan; ABG SRNE Ltd","owner_display_name":"Ally Bridge Group Innovation Capital Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":150000.0,"shares_display":"150,000","price_per_share":7.1865,"price_display":"7.19","price_state":"stated","total_value":1077975.0,"total_display":"1,077,975.00","total_whole":"1,077,975","shares_owned_after":1328529.0,"shares_owned_after_display":"1,328,529","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-02-07","filed_date":"2018-02-08","scope":"insider"},{"id":6144157,"accession":"0001209191-18-008299","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-008299","line_url":"/filing/0001209191-18-008299#line-1","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG Management Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG Innovation-SO Ltd; Li Bin; Ally Bridge LB Management Ltd; ABG II-SO Ltd; Yu Fan; ABG SRNE Ltd","owner_display_name":"Ally Bridge Group Innovation Capital Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":512912.0,"shares_display":"512,912","price_per_share":6.7541,"price_display":"6.75","price_state":"stated","total_value":3464258.9392,"total_display":"3,464,258.94","total_whole":"3,464,259","shares_owned_after":1478529.0,"shares_owned_after_display":"1,478,529","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-02-06","filed_date":"2018-02-08","scope":"insider"},{"id":6419317,"accession":"0001209191-18-008030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-008030","line_url":"/filing/0001209191-18-008030","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge LB Healthcare Master Fund Ltd; Li Bin; ABG II-SO Ltd; Ally Bridge LB Management Ltd; ABG SRNE Ltd; ABG Innovation-SO Ltd; Ally Bridge Group Capital Partners II, L.P.; Yu Fan; ABG Management Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.","owner_display_name":"Ally Bridge LB Healthcare Master Fund Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":70721.0,"shares_display":"70,721","price_per_share":8.0038,"price_display":"8.00","price_state":"stated","total_value":566036.7398,"total_display":"566,036.74","total_whole":"566,037","shares_owned_after":3041759.0,"shares_owned_after_display":"3,041,759","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-02-05","filed_date":"2018-02-07","scope":"insider","n_lines":3},{"id":6041090,"accession":"0001104659-18-005307","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001104659-18-005307","line_url":"/filing/0001104659-18-005307","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge LB Management Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG SRNE Ltd; Li Bin; Yu Fan; ABG Innovation-SO Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG II-SO Ltd; ABG Management Ltd","owner_display_name":"Ally Bridge LB Management Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":235156.0,"shares_display":"235,156","price_per_share":7.6527,"price_display":"7.65","price_state":"stated","total_value":1799578.3212,"total_display":"1,799,578.32","total_whole":"1,799,578","shares_owned_after":3079242.0,"shares_owned_after_display":"3,079,242","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-01-30","filed_date":"2018-01-31","scope":"insider","n_lines":3},{"id":6041080,"accession":"0001104659-18-005307","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-18-005307","line_url":"/filing/0001104659-18-005307","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Ally Bridge LB Management Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Healthcare Master Fund Ltd; ABG SRNE Ltd; Li Bin; Yu Fan; ABG Innovation-SO Ltd; Ally Bridge Group Capital Partners II, L.P.; ABG II-SO Ltd; ABG Management Ltd","owner_display_name":"Ally Bridge LB Management Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":74844.0,"shares_display":"74,844","price_per_share":7.6063,"price_display":"7.61","price_state":"stated","total_value":569285.9172,"total_display":"569,285.92","total_whole":"569,286","shares_owned_after":3203575.0,"shares_owned_after_display":"3,203,575","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-01-29","filed_date":"2018-01-31","scope":"insider","n_lines":3},{"id":4527919,"accession":"0001104659-17-025040","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-17-025040","line_url":"/filing/0001104659-17-025040#line-1","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"Yu Fan; Li Bin; ABG SRNE Ltd; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Management Ltd; ABG Management Ltd; Ally Bridge LB Healthcare Master Fund Ltd; ABG II-SO Ltd; Ally Bridge Group Capital Partners II, L.P.","owner_display_name":"Yu Fan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":550000.0,"shares_display":"550,000","price_per_share":2.0,"price_display":"2.00","price_state":"stated","total_value":1100000.0,"total_display":"1,100,000.00","total_whole":"1,100,000","shares_owned_after":1991441.0,"shares_owned_after_display":"1,991,441","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-04-19","filed_date":"2017-04-21","scope":"insider"},{"id":5313940,"accession":"0001104659-17-023841","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-17-023841","line_url":"/filing/0001104659-17-023841","is_derivative":false,"issuer_cik":"0000850261","issuer_name":"Sorrento Therapeutics, Inc.","issuer_ticker":"SRNE","issuer_name_source":null,"issuer_url":"/issuer/0000850261","owner_cik":null,"owner_name":"ABG SRNE Ltd; Ally Bridge LB Healthcare Master Fund Ltd; Li Bin; Ally Bridge Group Capital Partners II, L.P.; Ally Bridge Group Innovation Capital Partners III, L.P.; Ally Bridge LB Management Ltd; ABG II-SO Ltd; ABG Management Ltd; Yu Fan","owner_display_name":"ABG SRNE Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500000.0,"shares_display":"2,500,000","price_per_share":2.0,"price_display":"2.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":1500000.0,"shares_owned_after_display":"1,500,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-04-13","filed_date":"2017-04-17","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000850261","name":"Sorrento Therapeutics, Inc.","url":"/issuer/0000850261","role":"Ten percent owner","n_filings":6,"first_seen":"2017-04-17","last_seen":"2018-09-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001668028","retrieved_at":"2026-08-23T12:32:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}